Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 7
2019 7
2020 8
2021 12
2022 8
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies: Preliminary Evidence From a Clinical Pilot Study.
Trautwein NF, Hinterleitner C, Kiefer LS, Singer S, Mattern S, Schwenck J, Reischl G, Sipos B, Lauer UM, Dittmann H, Zender L, la Fougère C, Hinterleitner M. Trautwein NF, et al. Among authors: hinterleitner c. Clin Nucl Med. 2024 Mar 1;49(3):207-214. doi: 10.1097/RLU.0000000000005006. Epub 2024 Jan 23. Clin Nucl Med. 2024. PMID: 38271237
Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction.
Amor C, Fernández-Maestre I, Chowdhury S, Ho YJ, Nadella S, Graham C, Carrasco SE, Nnuji-John E, Feucht J, Hinterleitner C, Barthet VJA, Boyer JA, Mezzadra R, Wereski MG, Tuveson DA, Levine RL, Jones LW, Sadelain M, Lowe SW. Amor C, et al. Among authors: hinterleitner c. Nat Aging. 2024 Mar;4(3):336-349. doi: 10.1038/s43587-023-00560-5. Epub 2024 Jan 24. Nat Aging. 2024. PMID: 38267706 Free PMC article.
Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3.
Hinterleitner M, Pfeiffer R, Trautwein NF, Sipos B, Singer S, Nadalin S, Königsrainer A, Lauer UM, la Fougère C, Zender L, Hinterleitner C. Hinterleitner M, et al. Among authors: hinterleitner c. Front Endocrinol (Lausanne). 2024 Jan 8;14:1285529. doi: 10.3389/fendo.2023.1285529. eCollection 2023. Front Endocrinol (Lausanne). 2024. PMID: 38260136 Free PMC article.
Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction.
Amor C, Fernández-Maestre I, Chowdhury S, Ho YJ, Nadella S, Graham C, Carrasco SE, Nnuji-John E, Feucht J, Hinterleitner C, Barthet VJA, Boyer JA, Mezzadra R, Wereski MG, Tuveson DA, Levine RL, Jones LW, Sadelain M, Lowe SW. Amor C, et al. Among authors: hinterleitner c. Res Sq [Preprint]. 2023 Sep 26:rs.3.rs-3385749. doi: 10.21203/rs.3.rs-3385749/v1. Res Sq. 2023. PMID: 37841853 Free PMC article. Updated. Preprint.
NOTCH3 missense mutations as predictor of long-term response to gemcitabine in a patient with epithelioid hemangioendothelioma.
Schmidt M, Mattern S, Singer S, Schulze M, Biskup S, Krumm P, Lauer UM, Zender L, Hinterleitner C, Hinterleitner M. Schmidt M, et al. Among authors: hinterleitner c. J Cancer Res Clin Oncol. 2023 Aug;149(9):6753-6757. doi: 10.1007/s00432-023-04598-1. Epub 2023 Feb 7. J Cancer Res Clin Oncol. 2023. PMID: 36749424 Free PMC article. Review.
46 results